Despite the impressive advances in the diagnosis and treatment of prostate cancer achieved over the past decade, several basic questions remain unanswered. The utility of prostate-specific antigen (PSA) as a screening tool and the use of systemic chemotherapy in patients with advanced disease are two such topics. As with all dilemmas in medicine, clinical data obtained from high-volume studies serve to refine our understanding, prompting the formulation of clinical pathways, whose subsequent execution by individual practitioners should result in better patient care. However, this study-to-clinic transformation cannot be complete in the absence of one important denominator: the studies' generalizability.

The majority of clinical studies in prostate cancer have been characterized by exceedingly low participation rates of African-American men. As a recent analysis of us...

Article PDF first page preview

Article PDF first page preview
Article PDF first page preview
You do not currently have access to this article.